{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:00:11Z","timestamp":1792083611545,"version":"4.4.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008488","name":"Stiftelsen Alma och K. A. Snellman S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008488","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Finnish Rheumatic Disease Research Foundation"},{"DOI":"10.13039\/100008723","name":"Suomen L\u00e4\u00e4ketieteen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003125","name":"Suomen Kulttuurirahasto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003125","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005744","name":"Lastentautien Tutkimuss\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005744","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004212","name":"P\u00e4ivikki ja Sakari Sohlbergin S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004212","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>The aim of this study was to analyze the usefulness of myeloid-related protein 8\/14 (MRP8\/14) in the prediction of disease course in a real-world setting for patients with new-onset juvenile idiopathic arthritis (JIA), to identify the relationship between MRP8\/14 and disease activity using the physician\u2019s global assessment of disease activity (PGA), and determine whether the MRP8\/14 levels measured in serum and plasma are equally useful.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this prospective follow-up study, 87 new-onset non-systemic JIA patients were studied. Blood and synovial fluid samples were collected prior to any antirheumatic medication use. MRP8\/14 was measured from serum (S-MRP8\/14), plasma (P-MRP8\/14), and synovial fluid samples using ELISA.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The baseline MRP8\/14 blood levels were significantly higher in patients using synthetic antirheumatic drugs than in patients with no systemic medications at 1 year after diagnosis in serum (mean 298 vs. 198\u2009ng\/ml, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) and in plasma (mean 291 vs. 137\u2009ng\/ml, <jats:italic>P<\/jats:italic>\u2009=\u20090.001). MRP8\/14 levels at the time of JIA diagnosis were higher in patients who started methotrexate during 1.5-year follow-up compared to those who achieved long-lasting inactive disease status without systemic medications (serum: mean 298 vs. 219\u2009ng\/ml, <jats:italic>P<\/jats:italic>\u2009=\u20090.006 and plasma: 296 vs. 141\u2009ng\/ml, <jats:italic>P<\/jats:italic>\u2009=\u20090.001). P-MRP8\/14 was the most effective predictive variable for disease activity (by PGA) in linear multivariate regression model (combined to ESR, CRP, leukocytes, and neutrophils), whereas S-MRP8\/14 was not significant.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Blood MRP8\/14 levels at baseline seem to predict disease course in new-onset JIA patients. P-MRP8\/14 might be better than S-MRP8\/14 when assessing disease activity at the time of JIA diagnosis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12969-022-00701-x","type":"journal-article","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T12:12:57Z","timestamp":1655381577000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Myeloid-related protein 8\/14 in plasma and serum in patients with new-onset juvenile idiopathic arthritis in real-world setting in a single center"],"prefix":"10.1186","volume":"20","author":[{"given":"Paula L.","family":"Keskitalo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salla M.","family":"Kangas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirja","family":"Sard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tytti","family":"Pokka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virpi","family":"Glumoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petri","family":"Kulmala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2712-3903","authenticated-orcid":false,"given":"Paula","family":"V\u00e4h\u00e4salo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,16]]},"reference":[{"key":"701_CR1","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390\u20132."},{"key":"701_CR2","doi-asserted-by":"crossref","unstructured":"Consolaro A, Varnier GC, Martini A, Ravelli A. Advances in biomarkers for paediatric rheumatic diseases. Nat Rev Rheumatol. 2015;11(5):265\u201375.","DOI":"10.1038\/nrrheum.2014.208"},{"key":"701_CR3","unstructured":"Mariani A, Marsili M, Nozzi M, Faricelli R, Chiarelli F, Breda L. Serum calprotectin: review of its usefulness and validity in paediatric rheumatic diseases. Clin Exp Rheumatol. 2015;33(1):109\u201314."},{"key":"701_CR4","doi-asserted-by":"crossref","unstructured":"Foell D, Wittkowski H, Roth J. Mechanisms of disease: A \u201cDAMP\u201d view of inflammatory arthritis. Nat Clin Pract Rheumatol. 2007;3(7):382\u201390.","DOI":"10.1038\/ncprheum0531"},{"key":"701_CR5","doi-asserted-by":"crossref","unstructured":"Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, van Zoelen MAD, et al. Mrp8 and Mrp14 are endogenous activators of toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med. 2007;13(9):1042\u20139.","DOI":"10.1038\/nm1638"},{"key":"701_CR6","doi-asserted-by":"crossref","unstructured":"Malemud CJ. Myeloid-related protein activity in rheumatoid arthritis. Int J Inflam. 2011;2011:580295.","DOI":"10.4061\/2011\/580295"},{"key":"701_CR7","doi-asserted-by":"crossref","unstructured":"Holzinger D, Frosch M, Kastrup A, Prince FHM, Otten MH, van Suijlekom-Smit LWA, et al. The toll-like receptor 4 agonist MRP8\/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis. 2012;71(6):974\u201380.","DOI":"10.1136\/annrheumdis-2011-200598"},{"key":"701_CR8","doi-asserted-by":"crossref","unstructured":"Frosch M, Strey A, Vogl T, Wulffraat NM, Kuis W, Sunderk\u00f6tter C, et al. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum. 2000;43(3):628\u201337.","DOI":"10.1002\/1529-0131(200003)43:3<628::AID-ANR20>3.0.CO;2-X"},{"key":"701_CR9","doi-asserted-by":"crossref","unstructured":"Frosch M, Vogl T, Seeliger S, Wulffraat N, Kuis W, Viemann D, et al. Expression of myeloid-related proteins 8 and 14 in systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum. 2003;48(9):2622\u20136.","DOI":"10.1002\/art.11177"},{"key":"701_CR10","unstructured":"Berntzen HB, Fagerhol MK, Ostensen M, Mowinckel P, Hoyeraal HM. The L1 protein as a new indicator of inflammatory activity in patients with juvenile rheumatoid arthritis. J Rheumatol. 1991;18(1):133\u20138."},{"key":"701_CR11","unstructured":"Schulze zur Wiesch A, Foell D, Frosch M, Vogl T, Sorg C, Roth J. Myeloid related proteins MRP8\/MRP14 may predict disease flares in juvenile idiopathic arthritis. Clin Exp Rheumatol. 2004;22(3):368\u201373."},{"key":"701_CR12","doi-asserted-by":"crossref","unstructured":"Anink J, van Suijlekom-Smit LWA, Otten MH, Prince FHM, van Rossum MAJ, Dolman KM, et al. MRP8\/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis. Arthritis Res Ther. 2015;17(1):200.","DOI":"10.1186\/s13075-015-0723-1"},{"key":"701_CR13","doi-asserted-by":"crossref","unstructured":"Gerss J, Roth J, Holzinger D, Ruperto N, Wittkowski H, Frosch M, et al. Phagocyte-specific S100 proteins and high-sensitivity C reactive protein as biomarkers for a risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: A comparative study. Ann Rheum Dis. 2012;71(12):1991\u20137.","DOI":"10.1136\/annrheumdis-2012-201329"},{"key":"701_CR14","doi-asserted-by":"crossref","unstructured":"Foell D, Wulffraat N, Wedderburn LR, Wittkowski H, Frosch M, Ger\u00df J, et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission a randomized clinical trial. JAMA. 2010;303(13):1266\u201373.","DOI":"10.1001\/jama.2010.375"},{"key":"701_CR15","doi-asserted-by":"crossref","unstructured":"Otten MH, Prince FHM, Armbrust W, ten Cate R, Hoppenreijs EPAH, Twilt M, et al. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. JAMA. 2011;306(21):2340\u20137.","DOI":"10.1001\/jama.2011.1671"},{"key":"701_CR16","doi-asserted-by":"crossref","unstructured":"Moncrieffe H, Ursu S, Holzinger D, Patrick F, Kassoumeri L, Wade A, et al. A subgroup of juvenile idiopathic arthritis patients who respond well to methotrexate are identified by the serum biomarker MRP8\/14 protein. Rheumatology (Oxford). 2013;52(8):1467\u201376.","DOI":"10.1093\/rheumatology\/ket152"},{"key":"701_CR17","doi-asserted-by":"crossref","unstructured":"Bagri NK, Karmakar S, Haldar P, Lodha R, Kabra SK. Role of serum MRP8\/14 in predicting response to methotrexate in children with juvenile idiopathic arthritis. J Clin Rheumatol. 2021;27(8):e336\u2013e341.","DOI":"10.1097\/RHU.0000000000001406"},{"key":"701_CR18","doi-asserted-by":"crossref","unstructured":"Ganeva M, Fuehner S, Kessel C, Klotsche J, Niewerth M, Minden K, et al. Trajectories of disease courses in the inception cohort of newly diagnosed patients with JIA (ICON-JIA): the potential of serum biomarkers at baseline. Pediatric Rheumatol. 2021;19(1):64.","DOI":"10.1186\/s12969-021-00553-x"},{"key":"701_CR19","doi-asserted-by":"crossref","unstructured":"Hinze CH, Foell D, Johnson AL, Spalding SJ, Gottlieb BS, Morris PW, et al. Serum S100A8\/A9 and S100A12 Levels in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis: Relationship to Maintenance of Clinically Inactive Disease During Anti\u2013Tumor Necrosis Factor Therapy and Occurrence of Disease Flare After Discontinuation of Therapy. Arthritis Rheumatol. 2019;71(3):451\u20139.","DOI":"10.1002\/art.40727"},{"key":"701_CR20","doi-asserted-by":"crossref","unstructured":"Barendregt AM, Veldkamp SR, Hissink Muller PCE, van de Geer A, Aarts C, van Gulik EC, et al. MRP8\/14 and neutrophil elastase for predicting treatment response and occurrence of flare in patients with juvenile idiopathic arthritis. Rheumatology (Oxford). 2020;59(9):2392\u2013401.","DOI":"10.1093\/rheumatology\/kez590"},{"key":"701_CR21","doi-asserted-by":"crossref","unstructured":"Nordal HH, Fagerhol MK, Halse AK, Hammer HB. Calprotectin (S100A8\/A9) should preferably be measured in EDTA-plasma; results from a longitudinal study of patients with rheumatoid arthritis. Scand J Clin Lab Invest. 2018;78(1\u20132):102\u20138.","DOI":"10.1080\/00365513.2017.1419371"},{"key":"701_CR22","unstructured":"Wallace CA, Ruperto N, Giannini EH. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol. 2004;31(11):2290\u20134."},{"key":"701_CR23","doi-asserted-by":"crossref","unstructured":"Alberdi-Saugstrup M, Nielsen S, Mathiessen P, Nielsen CH, M\u00fcller K. Low pretreatment levels of myeloid-related protein-8\/14 and C-reactive protein predict poor adherence to treatment with tumor necrosis factor inhibitors in juvenile idiopathic arthritis. Clin Rheumatol. 2017;36(1):67\u201375.","DOI":"10.1007\/s10067-016-3375-x"},{"key":"701_CR24","doi-asserted-by":"crossref","unstructured":"Wulffraat NM, Haas PJ, Frosch M, de Kleer IM, Vogl T, Brinkman DMC, et al. Myeloid related protein 8 and 14 secretion reflects phagocyte activation and correlates with disease activity in juvenile idiopathic arthritis treated with autologous stem cell transplantation. Ann Rheum Dis. 2003;62(3):236\u201341.","DOI":"10.1136\/ard.62.3.236"},{"key":"701_CR25","doi-asserted-by":"crossref","unstructured":"La C, L\u00ea PQ, Ferster A, Goffin L, Spruyt D, Lauwerys B, et al. Serum calprotectin (S100A8\/A9): A promising biomarker in diagnosis and follow-up in different subgroups of juvenile idiopathic arthritis. RMD Open. 2021;7(2):e001646.","DOI":"10.21203\/rs.3.rs-138436\/v1"},{"key":"701_CR26","unstructured":"Ruperto N, Ravelli A, Migliavacca D, Viola S, Pistorio A, Duarte C, et al. Responsiveness of clinical measures in children with oligoarticular juvenile chronic arthritis. J Rheumatol. 1999;26(8):1827\u201330."},{"key":"701_CR27","doi-asserted-by":"crossref","unstructured":"Ruperto N, Ravelli A, Falcini F, Lepore L, Buoncompagni A, Gerloni V, et al. Responsiveness of outcome measures in juvenile chronic arthritis. Italian pediatric rheumatology study group. Rheumatology (Oxford). 1999;38(2):176\u201380.","DOI":"10.1093\/rheumatology\/38.2.176"},{"key":"701_CR28","unstructured":"Falcone A, Cassone R, Rossi F, Pistorio A, Martini A, Ravelli A. Inter-observer agreement of the physician\u2019s global assessment of disease activity in children with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2005;23(1):113\u20136."},{"key":"701_CR29","doi-asserted-by":"crossref","unstructured":"Backstr\u00f6m M, Tynj\u00e4l\u00e4 P, Ylijoki H, Aalto K, K\u00e4rki J, Pohjankoski H, et al. Finding specific 10-joint juvenile arthritis disease activity score (JADAS10) and clinical JADAS10 cut-off values for disease activity levels in non-systemic juvenile idiopathic arthritis: A Finnish multicentre study. Rheumatology (Oxford). 2016;55(4):615\u201323.","DOI":"10.1093\/rheumatology\/kev353"},{"key":"701_CR30","doi-asserted-by":"crossref","unstructured":"Rahman MT, Myles A, Gaur P, Misra R, Aggarwal A. TLR4 endogenous ligand MRP8\/14 level in enthesitis-related arthritis and its association with disease activity and TLR4 expression. Rheumatology (Oxford). 2014;53(2):270\u20134.","DOI":"10.1093\/rheumatology\/ket375"},{"key":"701_CR31","doi-asserted-by":"crossref","unstructured":"Alberdi-Saugstrup M, Zak M, Nielsen S, Herlin T, Nordal E, Berntson L, et al. High-sensitive CRP as a predictive marker of long-term outcome in juvenile idiopathic arthritis. Rheumatol Int. 2017;37(5):695\u2013703.","DOI":"10.1007\/s00296-017-3657-x"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-022-00701-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-022-00701-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-022-00701-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T12:19:11Z","timestamp":1655381951000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-022-00701-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,16]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["701"],"URL":"https:\/\/doi.org\/10.1186\/s12969-022-00701-x","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,16]]},"assertion":[{"value":"1 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Study consent was obtained from parents and patients or healthy children when appropriate. The ethics committee of the Northern Ostrobothnia Hospital District approved the study protocols (number 32\/2009 and 104\/2009).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors assign all rights and privileges and give consent for publication of this work to Pediatric rheumatology.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42"}}